Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Transdermal testosterone for postmenopausal women with stage B HFpEF
ACTRN12623000165684Phase 4Completed
- Sponsor
- Monash University
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of testosterone in heart failure with preserved ejection fraction (HFpEF) (2 arms), sponsored by Monash University. Primary endpoint: Change in cardiorespiratory fitness. Started Mar 2023; status: completed.
02
Drugs
testosterone
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on ACTRN12623000165684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000165684.